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ABSTRACT
Human adipose-derived stem cells (hASCs) have significant therapeutic
potential due to their ability to self-renew, differentiate down multiple lineages,
and modulate the immune system. In addition to these many benefits, hASCs
boast a minimally invasive harvesting procedure, making them a readily available
cell source for stem cell research and tissue regeneration (Ock, et al. 2016) (Abdi,
et al. 2008). Despite their broad use, very little is known about the mechanisms
that control cell fate.
One way to enhance our mechanistic understanding of differentiation is
through the systematic examination of the signaling pathways. The Notch
signaling pathway is a highly conserved, contact dependent, cell-to-cell signaling
cascade known to regulate cell state and multipotent differentiation of hASCs.
This pathway consists of four unique receptors and five unique ligands (Braune
and Lendahl 2016). Two receptors believed to play a significant role in regulating
osteogenic differentiation are Notch1 and Notch3.
Here the expression of Notch1 and Notch3 are characterized during
osteogenesis and the effect that siRNA-mediated knockdown of each receptor has
on osteogenic differentiation is evaluated. By studying changes in osteogenic
marker expression following a reduction in Notch expression and activity, we will
be able to determine how each receptor individually affects the osteogenic
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potential of hASCs and identify potential novel therapeutic targets to treat bone
damage and loss.
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CHAPTER 1
INTRODUCTION

1.1
1.1.1

Potential Roles for Manipulated Stem Cell Therapies

The Threat of Degenerative Bone Diseases
In our society, there are rising levels of degenerative bone diseases primarily

stemming from an increasingly aging population, but they can also be incited by
significant bone trauma. These injuries can result from a multitude of activities such as
sports injury, outdoor injury, and motorized vehicle accidents. Direct, physical injury of
the bone is not the only cause of damaged bone tissue. With a global trend of an
increasingly aging population, the prevalence of diseases such as osteoporosis are
continuing to rise (Aspray and Hill 2019). Even with the high prevalence of these injuries
and aging population, methods of bone repair have done little to evolve over the past
century; mainly relying on pins, screws, and plates to hold damaged and weakend bone
together until healed.
As humanity pushes further into deep space, the degradation of bone tissue from
exposure to microgravity is also rapidly becoming a significant concern (Axpe, et al.
2020). There is a significant amount of research surrounding the investigation of methods
for circumventing bone loss during extended stays in microgravity. These studies tend to
focus on providing artificial physical stimuli that simulate the effects of gravity on
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weight-bearing bones. Despite the decades of attempts, very little progress has been made
on this front. Even with the implementation of very complex and expensive exercise
equipment on the International Space Station, astronauts still suffer from debilitating
bone degradation (Axpe, et al. 2020) (Beguerisse-Díaz, Desikan and Barahona 2016)
(LeBlanc, et al. 2007). These diseases can lead to injuries similar to those seen in
physical accidents, but the main component of their pathology is an attack on the bone
tissue from a physiological front (Aspray and Hill 2019). The diverse nature of these
afflictions poses a significant challenge to doctors and researchers aiming to combat the
negative effects of these conditions.

Age-Related
Disease
Traumatic
Injury

Microgravity
Exposure
Bone
Degeneration
or Loss of
Tissue

Figure 1-1: Summary of the major factors leading to significant bone degradation.

1.1.2

Current Treatments for Bone Degeneration and Their Limited
While current treatments have produced effective results in the past, they tend to

come with some serious limitations. In the case of current polymer biomaterials used to
reinforce damaged tissue, these implants tend to be limited in their bio reactive capacity.
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The limited ability to interact with the surrounding tissue leaves a significant gap in the
potential for more complete healing of the injury (Yuan, et al. 2018). On top of the gap in
healing potential seen in both metallic and composite biomaterials, many patients that
have been treated with the historically popular metallic implants report pain, increased
sensitivity, corrosion, biofilm formation, and potential rejection (Přikrylová, Procházková
and Podzimek 2019). While biomaterial implants for major fractures can come with some
physical side effects, most pharmaceutical treatments of osteoporosis come with some
intense physiological side effects. The most common form of osteoporosis is due to
reduced estrogen production in postmenopausal women. This leads to most major
treatments being hormone treatments which can lead to various types of cancer as well as
producing a series of side effects in the circulatory system (Komm, et al. 2015) (Tella and
Gallagher 2014).
The current set of treatments for degenerative bone conditions have been in use
for some time now. As their side effects becoming increasingly apparent, researchers
have been pushed to develop modern alternatives. For the treatment of major fractures,
the use of bone implants is still the main approach but the composition and focus of the
implant has shifted. Modern developments in these implants seek to use new and
developing ceramic biomaterials that show significant bio reactive properties. Like earlier
methods, these implants seek to reinforce the fracture, but they go further and utilize the
body’s own regenerative capabilities (Ahadian and Khademhosseini 2018). Drug-related
therapeutic options will consistently be the most limited form of treatment due to their
highly prevalent long-term side effects; however, they can be highly beneficial for
patients that are not able to participate in consistent exercise, something proven to play a
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major role in maintaining bone mass (Santos, Elliott-Sale and Sale 2017). One of the
more novel treatments, and one with significant therapeutic potential, is the use of
autologous stem cells for wound healing and curbing the degradation of bone tissue.
Enhancing the therapeutic potential of these cells through the selective manipulation of
key molecular pathways is currently an active are of research. By using cells directly
harvested from the patient, these cells can then be implanted back into the patient after
they have been manipulated; thus, allowing the patient’s body to heal itself with its own
cells and hopefully allow for a restoration of original cellular function (Frese, Dijkman
and Hoerstrup 2016). This review will cover some of the current publications and data
that are working to develop and further our understanding of these potentially
revolutionary new technologies.
1.2

Shortcomings of Drug Therapies for Osteoporosis

1.2.1 Limitations of Bisphosphates and Estrogen Therapies
One of the oldest and most common methods of treating bone degeneration is the
use of bisphosphates. These drugs focus on limiting bone resorption in an attempt to
reach a balance between the anti-resorption properties of the bisphosphates and the
overactive resorption seen in diseases like osteoporosis. Even though this technique has
been shown to be effective in the past, this drug does not come without its own side
effects. The prolonged use of bisphosphates has been characterized by a substantial
increase in the risk of atypical femur fractures (AFFs). AFFs arise in the femurs of
patients that experience an overhardening and loss of flexibility in the long bones. This
change in the mechanical characteristics of the bone is believed to arise from the
prolonged prevention of bone resorption that eventually leads to the characteristic
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overhardened bone tissue. The adverse effects of this drug have led to a technique known
as “drug holidays” which are temporary suspensions of treatments intended to curb the
high risk of AFFs. However, even though these “holidays” do lead to a reduced risk of
these fractures, it leaves the patient vulnerable as they are not receiving the treatment that
they need (Skjødt, Frost and Abrahamsen 2019).
Even with the significant side effects of bisphosphates, they have proven to be a
consistent and effective treatment for osteoporosis. However, some forms of this disease
require a more specific pharmacological approach. In the case of postmenopausal
osteoporosis, loss in bone mineral density (BMD) primarily arises from the decrease in
estrogen production seen in postmenopausal women. The primary avenue of treatment for
this disease is the use of hormone replacement therapy, specifically estrogen and
progesterone therapy. While this treatment has shown consistent increases in BMD
similar to the results seen with bisphosphates, this therapy also comes with a list of side
effects. Particularly in older women undergoing this therapy, there has been a measurable
increase in risk for breast cancer, stroke, heart attack, and venous thromboembolism
(Tella and Gallagher 2014). The inherent risks of utilizing hormone replacement therapy
makes it a questionable long-term treatment for osteoporosis, but the shortcomings of
these treatments are the driving force behind the development of new drugs.
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Table 1-1: Summary of the properties of current treatments for bone degredation and
how manipulated stem cells can fill these niches.
Benefits
Side Effects
Alternatives
Drugs
Readily available
Increased risk of
Molecularly
and well
breast cancer and
manipulated stem
documented; easily potential
cells used to bolster
administered
overhardening of
existing osteoblasts
treatment for
the bone leading to and rescue bone
osteoporosis
increased fracture
mass density
risk
Implants
Highly tailorable
Possible
Biomaterials seeded
surfaces and
physiological
with molecularly
shapes; effective
rejection of the
manipulated stem
for trauma
implant, risk of
cells could lead to
infection, and lack
increased biological
of biological
reactivity and
reactivity
patient healing
potential

1.2.2

Modern Developments in Pharmaceutical Treatments
With the limitations of these common drug therapies, researchers are pushed to

develop alternatives to combat bone degeneration. The need for novel drug therapies has
led to the development of several new drugs all currently undergoing animal model
testing and clinical trials. Ipriflavone is a drug that is being developed to combat
postmenopausal osteoporosis (PMOP), one of the most common and well characterized
forms of bone degeneration. In one study seeking to study the effects of this drug in
ovariectomized mice (designed to simulate PMOP), it was shown that Ipriflavone
treatment led to a significant rescue of bone-mass density (BMD) when compared to
control mice (Gao, et al. 2018). Romosozumab is a monoclonal antibody that regulates
the resorption and formation of bone tissue. In one clinical trial, 7180 women with PMOP
were treated with romosozumab for 12 months and then switched to a denosumab
treatment for another 12 months. In this trial, patients treated with romosozumab for 12
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months saw a significantly reduced number of new vertebral fractures when compared to
placebo trials (Cosman, et al. 2016). Another method seeking to treat PMOP was
explored in a clinical trial seeking to determine an effective dosage for a therapy utilizing
a combination of denosumab and teriparatide treatment. It was determined that a higher
than the previously standard dosage of teriparatide combined with denosumab treatment
led to a higher increase in hip and spine BMD when compared to the standard dosage
(Tsai, et al. 2019). Even though these novel therapies exhibit promising results, the longterm efficacy of these treatments as well as their long-term side-effects remain to be seen.
This still leaves room for potential cell-based therapies to enhance or even replace these
novel drug therapies.
1.3

Human Adipose Derived Stem Cells

Human adipose-derived stem cells (hASCs) have significant therapeutic potential
due to their ability to self-renew, differentiate, and modulate the immune system. In
addition to these many benefits, hASCs require a minimally invasive harvesting
procedure, making them a readily available cell source for stem cell research and tissue
regeneration (Ock, et al. 2016) (Abdi, et al. 2008). hASCs have many properties that
make them clinically relevant as a therapeutic cell source for procedures seeking to
enhance, repair, or replace damaged tissue. These cells are known to be multipotent,
meaning that they have the potential to differentiate from a stem cell into multiple
different tissue types of a specified lineage. Human ASCs are known to differentiate into
cells of the mesoderm lineage including muscle, bone, fat, cartilage, and nerve tissue
indicating strong therapeutic potential for any situation where damaged tissue cannot be
repaired on its own (Zuk, et al. 2002). One of the major benefits to using hASCs is that
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they can be harvested from the afflicted person using lipo-aspiration from that patient’s
own fat tissue (Frese, Dijkman and Hoerstrup 2016). Through this procedure, the tissue
being used is autologous, meaning it is the patient’s own cells and there is no threat of an
immune response to the transplanted tissue. Human ASCs are already part of 81 clinical
trials and are used in dozens of outpatient treatment centers across the country for both
their immunomodulatory and regenerative properties (Search of: Recruiting, Not yet
recruiting, Active, not recruiting, Enrolling by invitation Studies | adipose stem cells List Results - ClinicalTrials.gov n.d.). Despite their broad use, however, the scientific
community still knows very little about the mechanisms that control cell fate and how
this information might enhance the therapeutic usage of these cells to treat injuries and
degenerative health conditions.
Self-Renewal
Blood

Adipose

Bone Marrow

Adipocyte

hASC

Osteoblast

Chondrocyte

Figure 1-2: Human adipose-derived stem cells (hASCs) have potential to differentiate
down multiple different cell lineages depending on a series of environmental stimuli.
Image Credit: Rachel Eddy

1.3.1 Wound Healing Properties of hASCs
One of the major challenges to utilizing cell-based therapies is the method of
harvesting the stem cells needed for the treatment. In the past, the most commonly used
stem cells for these therapies were bone marrow derived stem cells (BMSCs). While
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BMSCs do have immense therapeutic potential, they require a highly invasive harvesting
procedure that does not yield many viable cells. For this reason, researchers are
beginning to turn to adipose derived stem cells (ADSCs) for their ease of harvesting and
increased yield. The differentiation potential of the two cell types was explored in a
recent study seeking to understand how these cells could be used in a wound healing
scenario dealing with diabetic foot ulcers (DFUs). BMSCs were already shown to
drastically increase healing time and efficiency so ADSCs were tested in an identical
scenario. These researchers found that BMSCs and ADSCs displayed near identical
morphology, expression of cellular markers, VEGF secretion, and proliferation rates.
With the cells’ metabolic characteristics showing similar results, the researchers seeded
them onto collagen scaffolds which were grafted into DFUs of diabetic mice. After it was
established that BMSCs and ADSCs both showed similar levels of wound healing
potential, an identical experiment was established to compare healthy ADSCs and
ADSCs from diabetic patients. In this study, the diabetic cells showed almost no
decrease in therapeutic potential when compared to non-diabetic cells (Guo, et al. 2018).
This experiment demonstrated that there are multiple potential cell sources for use in
stem cell therapies with similar therapeutic potential.
1.4

Osteogenesis

Since hASCs differentiate into tissues of the mesoderm layer, they can provide a
consistent and effective platform to study the early regulatory processes of osteogenic
differentiation. Osteoblasts, the cells responsible for the synthesis and maturation of bone
tissue, are derived from mesenchymal stem cells where they are exposed to a
microenvironment favorable for osteogenesis (Luo, et al. 2019). However, the formation
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of bone tissue is not entirely reliant on osteoblasts. These cells will coordinate with
several different cell types such as osteoclasts and chondrocytes; both of which are also
derived from mesenchymal stem cells. Bone formation typically takes two different
forms: intramembranous ossification and endochondral ossification. While these
processes give rise to different types of bones (flat bones and long bones respectively),
they both center around the condensation of cells in the mesenchyme into calcified bone
tissue. However, it is intramembranous ossification that primarily involves osteoblasts
derived directly from mesenchymal stem cells (Qin, et al. 2016).
While osteogenesis shows significant interaction with other cell types derived
from the mesoderm, these osteogenic cells also interact with other cells located outside of
this shared germ layer. Osteocytes have been shows to have a deep link with endothelial
cells during the formation of bone tissue, specifically with cells involved in angiogenesis.
This linkage has been shown to produce developmental disorders of the bone tissue like
craniosynostosis and midfacial hypoplasia that are caused by dysregulation of
angiogenesis (Percival and Richtsmeier 2013). These claims of endothelial cells having
strong linkages to osteogenesis are not only seen in medical conditions. Researchers have
shown that endothelial cell-specific knockouts of the Notch pathway will significantly
inhibit blood vessel formation as well as reducing osteogenesis (Qin, et al. 2016).
1.4.1 Osteoblasts
One of the primary cell types involved in the repair of bone tissue is the
osteoblast. Osteoblasts are vital to the growth and formation of new bone tissue while
also playing a major role in maintaining existing bone tissue (Lee, et al. 2017). These
cells are one of the main cell types that researchers turn to when seeking to study the
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regulation of osteogenesis or as a potential cell source for novel regenerative therapies.
Primary human osteoblasts that have been either directly extracted or differentiated from
stem cells are of particular interest due to their behavior that closely mimics an in vivo
lineage when they are cultured in an in vitro setting. These characteristics have led the
osteoblasts, particularly those derived directly from harvested stem cells to the forefront
of clinical research in areas of osteogenic regulation and tissue repair (Czekanska, et al.
2012).
Due to osteoblasts having such high levels of clinical relevance, the regulation of
osteogenesis within these cells is of particular interest to researchers seeking to unlock
their potential. One of the most characterized routes of regulation in osteoblasts and preosteoblasts in through the transcription factor Runx2, a component in a family of
transcription factors that includes Runx1, Runx2, and Runx3. This transcription factor is
primarily found in osteoblasts and chondrocytes throughout most of their development. In
the case of osteoblasts, Runx2 sees an upregulation in expression with a peak in the
immature osteoblast stage before beginning to drop once the osteoblasts reach maturity.
This transcription factor has proven vital to the initiation and maturation of osteoblastic
differentiation many times over, but it can be most clearly seen in Runx2-deficient mice.
In these models, researchers saw that there was a severe lack of bone formation and even
an overall lack of osteoblasts in the mice’s tissue. Compounding research has shown that
Runx2 expression is vital for progenitor cells to commit to the osteoblastic lineage as
well as for the transcription of genes dealing with the production of bone matrix proteins
(Komori 2019).
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Figure 1-3: Both Runx2 and ALP show a consistent increase in expression levels that
peak around the 21 Day mark and begin to decrease until cells have differentiated into
mature osteoblasts (Day 28).

1.4.2 Osteoclasts
Osteoclasts are the second type of cell that plays a major role in the proper
modelling of bone tissue. These cells are responsible for the resorption of bone tissue, a
process vital to the proper formation of bone structure and developmental modification to
this bone structure. Examples of this can be seen in mice exhibiting dysregulations such
as osteopetrosis that leads to a deficiency in osteoclast activity. These mice tend to lack
the ability to produce bone marrow in the long bones while also displaying a lack of tooth
eruption. However, when these cells are over-active, they can cause severe damage to
bone tissue. These cells are seen to cause destruction of bone tissue in patients with
osteoporosis and those with highly metastatic osteosarcomas (Miyamoto 2011).
While osteoblasts and osteoclasts have opposite functions, it does not mean that
these cells are mutually exclusive. These two cell types work in tandem to achieve the
constant remodeling of the skeleton that is required to maintain proper homeostasis of the
tissue. While osteoblasts tend to take the spotlight due to their bone forming properties,
the tissue formed by these cells is not immortal. It is the role of the osteoclast to break
down the aging bone tissue produced by the osteoblast to recycle components and make
room for new bone formation. These two cells also work in tandem to regulate each
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other’s differentiation and perform general communication through avenues such as the
formation of gap junctions between the two cells and cytokine signaling. This
communication has been shown to illicit phenomena such as the initiation of one cell
type’s differentiation and the apoptosis of osteoclasts through osteoblast-derived
signaling (Chen, et al. 2018).
1.5

Notch and Osteogenesis

The Notch signaling pathway is a highly evolutionarily conserved, contactdependent, cell-to-cell signaling pathway that has been shown to play a major role in all
stages of development (Braune and Lendahl 2016). While Notch plays many roles in
tissue development, perhaps one of the most studied roles of the pathway is its ability to
regulate the differentiation and proliferation of mesenchymal stem cells. Notch has
primarily been shown to play a role in determining cell fate in differentiating tissue;
guiding stem cells along specific differentiation pathways based on specific receptorligand interactions (Sandel, et al. 2018). The prevalence of the Notch pathway’s role in
regulating mesenchymal stem cell differentiation has led to a series of studies aimed at
examining this pathway’s role in many different forms of differentiation.
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Figure 1-4: The Notch signaling pathway sends and receives signals between
neighboring cells in a contact dependent manner. These signals have been shown to play
an extensive role in regulating many different types of differentiation in adult stem cells.
Figure Credit: Mengcheng Liu

Through the use of transgenic mouse models, Zanotti et al. studied the effects of
Notch in scenarios of both over and under expression. It was observed that not only does
the Notch pathway play a major role in regulating osteogenesis by inhibiting
differentiation, they also concluded that Notch can interact and regulate other regulatory
pathways, specifically Wnt and BMP signaling (Zanotti, et al. 2008). In the case of this
study, the data shows that Notch inhibition could lead to increased osteogenesis in cells
being used to treat bone degradation. Due to Notch’s supposedly inhibitory action in
osteogenesis, it shows potential to be a significant therapeutic target to induce higher
levels of osteogenic differentiation. Studies such as this are vital in establishing a
foundation of knowledge from which future studies and therapies can be built upon.
While this study does show that the Notch pathway inhibits osteogenic
differentiation, it is somewhat broad and tends to focus on the pathway as a whole rather
than the role of individual receptors and ligands. If molecular manipulation of stem cells
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is to be used in a clinical setting, then these manipulations need to be highly specific and
the potential side effects of these manipulations need to be carefully observed. A study
performed by He et al. aimed to define the specific effects that the Notch1 receptor has
on osteogenesis. The findings of this research showed that after inhibition at both the
protein and transcript level, Notch1 plays a major inhibitory role in regulating
osteogenesis. This was observed after there was a sharp increase in osteogenic
differentiation following the inhibition of this receptor. The researchers also wanted to
study whether or not the inhibition of this pathway could lead to tumorigenesis. They
studied this by observing expression levels of the p53 gene, a well-known tumor
suppressor, as well as observing any changes in cell viability before and after the
inhibition of Notch1. There was both an increase in p53 expression and a decrease in cell
viability associated with Notch1 inhibition, thus pointing to the possibility of potential
tumors forming if these manipulated cells were to be implanted in a patient (He and Zou
2019).
1.6

Conclusion

Though there are many factors that must be understood in order to develop a cellbased therapy that could be used to combat various forms of bone degeneration, the
application of stem cells for regenerative therapies still exhibits promise as a novel
treatment for bone degeneration. With an aging population, the possibility of long-term
side effects from the current pharmaceutical treatments for bone degeneration continues
to be a concern, as the increase in life span is not pushing the onset of these diseases
further back. These long-term complications also rule out the possibility of these drugs
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being used to combat the bone degeneration seen in microgravity; an environment that
will continue be occupied by more people in the coming years.
hASCs have shown their therapeutic potential in the wound healing sector with
capabilities very similar to those of the much more costly and painful to extract BMSCs.
While the promise of successful wound healing is enlightening, these studies were
performed with undifferentiated hASCs. The use of hASCs as a cell source to be used for
more tissue type specific therapies utilizing their multipotency is still a relatively new
concept that requires the hurdling of multiple obstacles and an expansion of the current
knowledgebase. At the heart of the difficulties plaguing the development of this
technology is the lack of a thorough understanding of the regulatory mechanisms of these
cells. In order to fully unlock the therapeutic potential of hASC multipotency, how these
cells handle differentiation must be understood.
In the case of osteogenic differentiation, understanding how this differentiation
works and how it is regulated is vital to producing a therapy derived from hASCs. While
osteogenesis on a tissue-wide level has been shown to be a complex process that requires
many different cell types, it seems that the bone-forming osteoblast boasts the highest
potential as a cell lineage target for hASC therapies. The thorough characterization of its
transcriptional regulators as well as its defined ability to regulate other cell types, such as
the bone-resorbing osteoclast, shows promise as a cell type that could seriously curb the
degenerative effects of diseases such as osteoporosis if incorporated into a cell
transplantation therapy. However, if this cell-based therapy is to be safely implemented,
the methods of molecular regulation must be more deeply explored.
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Figure 1-5: The use of manipulated stem cells shows potential as a therapy that can
either replace or work in tandem with currently available treatments for both osteoporosis
and severe bone trauma.

While it has been shown that there are a series of signaling pathways that work in
tandem to produce the complex process of osteogenesis, the Notch signaling pathway is
one that seems to show promise as a regulatory target. While targeting the Notch pathway
would only cause direct manipulations to Notch itself, these manipulations could have
effects on other pathways that also play a role in osteogenesis. Notch has been shown to
initiate crosstalk with other pathways such as Wnt and BMP signaling, both of which are
known to regulate stem cell differentiation throughout development. The interaction with
other pathways is not the only phenomenon that alludes to its promise as a therapeutic
target. Notch has been shown to have a direct effect on osteogenic differentiation,
especially in the earlier stages of osteoblast formation. However, direct manipulation of
the pathway has been shown to cause some adverse side effects. For example, upon
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inhibiting the Notch1 receptor, researchers have observed a distinct increase in p53
expression as well as a reduction in cell viability, both of which are factors that point to
potential tumorigenesis.
Even though direct manipulation of the Notch pathway poses some obstacles, there is still
immense potential for this pathway to develop into a widely used therapeutic target to
increase the potential of hASCs as a cell source for novel therapies seeking to combat
bone degeneration. These obstacles are the reason that the effects of this pathway on
osteogenesis must be further studied and characterized to pave the way for future
research to build upon. With a substantial knowledgebase on how this pathway regulates
osteogenesis, specifically in osteoblasts, researchers can develop life-saving methods to
combat these afflictions while also contributing to the world-wide push to venture deeper
into our solar system.
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CHAPTER 2
METHODS

2.1
2.1.1

Cell Culture

Culturing hASCs
All cells were initially cultured in a Complete Culture Media (CCM) comprised of

203.75 mL of 1X MEM Alpha (Gibco; 12561-049), 41.25 mL of Fetal Bovine Serum
(ATLANTA Biologicals; S11150), 2.5 mL of 200mM L-Glutamine (Gibco; 25030-081),
and 2.5 mL of Pen Strep (Gibco; 15140-122). Ingredients were combined into a 250 mL
Corning filter system (VWR 28199-770) and filtered under a sterile hood.
2.1.2

Cell Thawing
A cell line (Obatala 70926) of human adipose derived stem cells (hASCs)

obtained from Obatala Sciences (New Orleans, Louisiana, United States) were thawed at
37°C and transferred to a conical tube containing warmed CCM. The cells were then
isolated by centrifuging them at 1,500 RPM before being resuspended and transferred to
a 10 cm tissue culture-treated plate containing CCM. The media on this plate was then
changed the following day and then every 48 hours until the cells reached 70-80%
confluency.
2.1.3

Passaging Cells
Upon reaching 70-80% confluency, cells were detached from the plate by adding

0.25% Trypsin-EDTA (Life-Technologies 25200-056) and incubating at 37°C for 3
minutes. CCM was then added to the plates to neutralize the trypsin and this solution was
collected in a conical tube to be centrifuged at 1,500 RPM. Cells were then isolated and
resuspended in CCM where a sample was stained with 0.4% Trypan Blue for cell
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counting. The cells were counted on a Countess II FL Hemocytometer and a Countess II
FL machine. The live cell count was then used to determine the volume of cells needed to
seed at the densities outlined in Table 2-1. The media was then changed on the newly
seeded plates 24 hours after passaging and then every 48 hours until initiation of
differentiation or collection.
Table 2-1: Cell seeding density depenent on culture plate size

2.1.4

Plate Size

# of Cells per Plate/ Well

Total Volume of CCM

10-cm

100,000

10 mL

6-cm

45,000

3 mL

6-well

20,000

2 mL

siRNA Knockdowns
Upon reaching 40-45% confluency, cells were exposed to a transfection solution

comprised of 1X Opti-MEM I (Gibco; 31985-062), Lipofectamine RNAiMAX Reagent
(Invitrogen; 56531), and an siRNA solution containing negative control, Notch1, or
Notch3 siRNA. This transfection solution was then combined with CCM and added to the
wells. The day following the siRNA knockdown, the media was changed, and cells were
cultured for 14 days in lab-made osteogenic media with media changes every 48 hours.
2.1.5

Osteogenesis
Cells were seeded onto 6-well plates containing CCM according to Table 2-1

with media being changed every 48 hours until cells reached 55-65% confluency. The
media was then switched to a purchased osteogenic media (Thermo Scientific A1007201)
or a lab-made osteogenic media comprised of 89% DMEM/F-12 (Gibco 10565018), 10%
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Fetal Bovine Serum (ATLANTA Biologicals; S11150), and 1% Pen Strep (Gibco;
15140-122) with the addition of 1 nM Dexamethasone, 10 mM Beta-Glycerophosphate,
and 50 uM L-Ascorbic Acid 2-Phosphate. The cells were cultured for up to 14 days with
media being changed every 48 hours.
2.2
2.2.1

Gene Expression Analysis

RNA Collection and Extraction
Cellular RNA was collected using a Trizol reagent (Thermo Scientific 15596018)

according to the manufacturer’s protocol where the lysate was then stored at -80°C.
Prior to the extraction process, the collected lysate was allowed to thaw at room
temperature. Chloroform was then added to the samples where they were agitated and
allowed to incubate at room temperature. The samples were then centrifuged at 4°C and
12,000x G. After centrifugation, the clear supernatant was collected and the remaining
phenol waste was discarded. 5mg/mL glycogen (ThermoFisher Scientific R0551) was
then added to the samples and followed by 100% isopropanol where they were then
incubated at room temperature. After another round of centrifugation at 4°C and 12,000x
G, an RNA pellet was isolated and the remaining isopropanol was removed. The RNA
pellet was then washed with 75% ethanol and centrifuged at 4°C and 7,500x G. The
ethanol was then removed and the pellet was allowed to dry until resuspension in
nuclease-free water (VWR 10220-404) and stored at -80°C. The RNA would later be
quantified using a spectroscopy program on a Cytation 5 BioTek Plate Reader.
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2.2.2

cDNA Synthesis
1 ug of extracted RNA, nuclease-free water, and qSctriptTM cDNA SuperMix

(Quantabio 95048-100) were used to synthesize cDNA according to the manufacturer’s
protocol.
2.2.3

RT-qPCR
(Reverse Transcription-Qualitative Polymerase Chain Reaction) RT-qPCR was

performed using a technical triplicate by combining PowerUp SYBR Green Master Mix
(Applied Biosystems A25742), nuclease-free water, forward and reverse primers (Table
2-2), and 1 uL of CDA per reaction in a 96-well plate. The reaction was then run using a
StepOnePlusTM Applied Biosystems machine standard quantitation experiment. The data
from this experiment was then plotted on a Comparative CT (ΔΔ CT) curve.
Table 2-2: Forward and reverse primers used for RT-qPCR
Gene

Forward Sequence

Reverse Sequence

Product Size (bp)

gapdh

ACTAGGCGCTC

CAATACGACCAA

99

ACTGTTCTCT

ATCCGTTGACT

CACGCTGACG

GGCACGATTT

GAGTACAAGT

CCCTGACCA

CACCCTTACCT

TTCGGACCAGT

GACCCCATCC

CTGAGAGGGA

CTCACTACCAC

TCAATATGGTCG

ACCTACCTG

CCAAACAGATTC

CTAACTCCTTA

CATGATGACAT

GTGCCAGAG

TCTTAGCCAC

notch1

notch3

runx2

alp

56

81

320

125
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2.3
2.3.1

Protein Expression Analysis

Protein Extraction
6 cm plates were rinsed with PBS (ThermoFisher Scientific 10010023) before the

addition of 1X RIPA lysis buffer containing a protease and phosphatase inhibitor. The
cells were then scraped and the lysate was collected in tubes for a 30 minute rotation at
4°C. The samples were then centrifuged at 12,000 RPM at 4°C for 20 minutes where the
resulting supernatant was removed and stored at -80°C.
2.3.2

Bradford Assay
A protein dye and distilled water were combined to form a 20% Bradford buffer

prior to the creation of samples. BSA, water, and buffer were mixed to form 6 standards
of increasing protein concentration. Protein samples with unknown concentrations were
mixed with Bradford buffer and distilled water. All samples were pipetted in duplicate
into a clear-bottom 96-well plate before determining protein concentration in a Cytation 5
BioTek plate reader.
2.3.3

Western Blot
Prior to the experiment, a 10% running buffer and a 10% Tris/Glycine buffer were

prepared and stored in a refrigerator. A Laemmli buffer (Biorad 1610737), water, and
protein solution was prepared based on the protein concentrations provided by Bradford
assay. Samples were then boiled at 100°C and spun down before being loaded into an
electrophoresis gel (Biorad 456-1084) alongside a protein standard (Biorad 1610376).
This gel was then run in an electrophoresis apparatus containing to previously prepared
10% running buffer for 90 minutes at 120V.
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Following electrophoresis, the gel was transferred onto a PVDF membrane
(Biorad 1704156) in an electrophoresis apparatus run in the previously prepared 10%
Tris/Glycine transfer buffer for 60 minutes at 100V. After the transfer process, the
membrane was cut into sections dependent on the location of the protein of interest based
on size in kDa. The membrane sections were then blocked in a non-fat milk blocking
buffer (Cell Signaling Technology 99995) for 120 minutes. During the blocking process,
primary antibody solutions were prepared using the non-fat milk buffer. After blocking,
the membranes were probed in the primary antibody solution overnight in a refrigerator.
Table 2-3: Primary and Seconday Antibodies Used in Wester Blot Analysis
Antibody
Anti-GAPDH
Rabbit pAb
Anti-Notch3 Rabbit
mAb
Goat Anti-Rabbit
IgG H&L

Company
Abcam

Call Number
ab9485

Concentration
1:3000 Dilution

Cell Signaling

5276s

1:1000 Dilution

Abcam

ab150077

1:1000 Dilution

2.4
2.4.1

Osteogenic Characterization

Alizarin Red Stain
Media was removed from the 6-well plates after a 7 or 14-day osteogenic

differentiation period and the wells were washed with 150 mM NaCl solution. An icecold 70% ethanol solution was then added to the wells and the cells were allowed to fix
for one hour. The ethanol was then removed, and the cells were washed with DI water
before adding a 2% alizarin red solution (Lifeline Cell Technology CM 0058). After 15
minutes of staining the alizarin solution was removed and the cells were washed with DI
water before being imaged in a Cytation 5 BioTek plate reader.
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CHAPTER 3
RESULTS

3.1

Knowledge of Notch Signaling is Vital to Understanding of Osteogenesis
The differentiation of stem cells is a highly regulated process that involves many

mechanisms working together to attain the desired lineage. One of the most potent
methods to increase cellular differentiation is the selective inhibition or activation of
signaling pathways that carry out this regulation. Before manipulations such as this can
occur, researchers must fully define the role and mechanism of action for a given
pathway. One of the most actively researched of these regulatory pathways is the Notch
signaling pathway. This pathway is well known for its significant role in guiding the
differentiation of stem cells at all levels of development, but the exact role of its
components in specific types of differentiation remains unknown.
One way to enhance our mechanistic understanding of differentiation is through
the systematic examination of signaling pathways that control cell fate. The Notch
signaling pathway is a highly conserved signaling cascade known to regulate cell state
and multipotent differentiation of hASCs. The Notch pathway is involved in the
regulation of many differentiation processes where it plays a key role in initiating and
maintaining the cellular modification of these processes. The Notch pathway is a cell-tocell contact-dependent signaling pathway; meaning that the pathway is activated when a
receptor on the surface of the signal-receiving cell encounters a specific ligand on the
surface of a signal-presenting cell. The pathway consists of four unique receptors and five
unique ligands. These receptors are Notch1, Notch2, Notch3, and Notch4 while the
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receptors are DLL-1, DLL-3, DLL-4, Jagged1, and Jagged2 (Braune and Lendahl 2016).
The gene expression profile and subsequent phenotype that a cell adopts depends on
which receptor binds to which ligand. This is crucial during tissue development because
it establishes coordination between cells during the phases of proliferation (cell division),
differentiation, and maturation of differentiated cells (Braune and Lendahl 2016).

Figure 3-1: Diagram representing the mechanism of the Notch signaling pathway.
Figure Credit: Mengcheng Liu
With the knowledge that osteogenesis is a large-scale process involving
interactions between multiple cell types, studying a cell-to-cell signaling pathway like
Notch has potential to elicit valuable insight into the molecular regulation of this process.
By characterizing how the Notch pathway changes during hASC osteogenesis, valuable
knowledge of the role of Notch1 and 3 in this process stands to be gained. Through the
use of siRNA knockdowns, the effects of these receptors can be more precisely
determined while also gaining insight into how molecular manipulation of this pathway
could be used to enhance the osteogenic potential of hASCs for therapeutic applications.
Through these assays, we have been able to determine that Notch3 plays an active role in
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initiating and maintaining osteogenic differentiation in hASCs as seen by its increase in
expression and negative impact on osteogenesis following siRNA-mediated knockdown.
Notch1 appears to not have a role in promoting osteogenesis; however, the decrease in
expression seen at the 14-day time point seems to allude to a potential role in preosteoblast proliferation which would echo findings seen in other literature (He and Zou
2019). The opposing effects seen in these two receptors suggests that the Notch signaling
pathway can take on many different roles in regulating differentiation through the use of
multiple receptor interactions.
3.1.1

Proper Cell Culture Conditions Are Needed for Osteogenesis
Prior to characterization of Notch signaling, culture conditions for efficient and

reproducible osteogenic differentiation needed to be optimized. This included examining
cell density prior to inducing differentiation and duration of differentiation.
Cell Density.
In order to produce proper in vitro testing, it is vital that the cells form a uniform
layer across the bottom of the culture plate. This ensures that any cell-to-cell
communication mechanisms necessary for proper differentiation can interact. Initially,
osteogenesis was initiated by adding the Purchased Media the day after cells were
passaged onto 6-well plates. This yielded a “clumping” phenomenon that was deemed to
be due to low density and the increased tension associated with osteocyte calcification
[Figure 3-2]. We repeated differentiation by seeding cells and waiting for them to reach a
confluency of 55-60%, at which point they were in a a uniform and stable “cell sheet.”
This ensured more consistent cell-cell contact across the plate rather than in concentrated
areas.
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Figure 3-2: Phase contrast image displaying the “clumping” phenomenon seen from
initiating osteogenesis too early. Image taken at 10x magnification.

Duration of Differentiation.
Once we determined proper density for inducing differentiation, cells we
attempted to culture cells for up to 21 days under osteogenic conditions. The cells were
very inconsistent over this period of time, with most wells not able to get past 17-19 days
of differentiation before we noticed dramatic changes in cell behavior. Between 17 and
19 days after inducing differentiation, the cells would begin to lift off of the plate due to
the increased tension associated with osteogenesis. Due to this phenomenon, the final
timepoint for collection was determined to be 14 days into differentiation.
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3.1.2

Lab-Made Media Displays Highest Osteogenic Potential

To ensure the reproducible and efficient initiation of osteogenesis, two different media
recipes were tested. We compared purchased media, which offered consistency in
manufacturing but came with the need to frequently order, wait on delivery, and an
additional expense to the lab. We also looked through the literature and identified a
recipe we could make in the lab that would save the lab money and ensure fresh media
generation for repeated experiments. The testing was conducted by culturing cells in
parallel the Lab-Made Media and the Purchased Media for up to 14 days. qRT-PCR
assessment of runx2, a master regulator of osteogenesis, showed that the Lab-Made
Media displayed higher levels of runx2 expression at the Day 7 timepoint when
compared to the Purchased Media [Figure 3-3]. This was repeated several times and
demonstrated the ability to reproducibly and efficiently initiate osteogenic differentiation
of hASCs. Once the Lab-Made Media was determined to produce higher levels of
differentiation, effects of the media on differentiation were examined more closely. The
expression of runx2 and an additional osteogenic marker, alp, were evaluated to ensure
consistent differentiation [Figure 3-4]. The observed increase in expression of both runx2
and alp shows that this media is initiating consistent osteogenesis for a prolonged period
of time. With verification that the Lab-Made Media produces high quality levels of
osteogenesis compounded with the logistical and financial benefits, this was the media
that was chosen to be used in further experiments.
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Figure 3-3: Characterization of runx2 expression in Purchased Media (P.M.) and LabMade Media (L.M.) samples. A qRT-PCR observing the difference in runx2 expression
between Day 0 and Day 7 samples cultured in Lab-Made Media (p=0.025564). B qRTPCR observing the difference in runx2 expression between Day 0 and Day 7 samples
cultured in Purchased Media (p=0.726747). Experiments were run in biological triplicate
with n=3.
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Figure 3-4: Characterization of runx2 and alp expression in samples cultured in the LabMade Media. A qRT-PCR observing the difference in runx2 expression between Day 0
and Day 7 samples (p=0.044647). B qRT-PCR observing the difference in runx2
expression between Day 0 and Day 14 samples (p=0.002263). C qRT-PCR observing the
difference in alp expression between Day 0 and Day 7 samples (p=0.0000625). D qRTPCR observing the difference in alp expression between Day 0 and Day 14 samples
(p=0.000194). Experiments were run in biological triplicate with n=3.

To further characterize the difference in osteogenic potential between the LabMade and Purchase Media, a series of alizarin stains was performed [Figure 3-5].
Alizarin stains stain the calcium deposits that develop in the extracellular matrix excreted
by developing osteoblasts. The staining of these deposits give a very good qualitative
measure of osteogenic potential of the differentiating cells. Mixed results were seen in the
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Purchased Media samples which displayed bright red staining but the characteristic
“film” that grows over differentiating osteocytes would consistently detach after adding
the stain. In Lab-Made Media samples, a different brand of alizarin solution was used due
to limited stock of the previous stain used on the Purchased Media samples. With the
stain used on the Lab-Made Media samples, there were many challenges with getting the
stain to produce the characteristic red color. Different fixing and rinsing reagents were
tried including fixing the cells with 70% ethanol instead of formalin and rinsing the cells
with saline instead of PBS. When the fixing reagent was switched to ethanol and the
rinsing reagent was switched to saline, the red color was still not present, but staining
quality was much higher [Figure 3-6]. After consulting with Dr. Jeffrey Gimble’s lab at
Obatala Sciences, we determined that our issue was most likely due to the pH of our
alizarin solution. However, difficulties with equipment used to determine the solution’s
pH meant that the pH could not be properly adjusted. This issue will continue to be
explored in the future.
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Figure 3-5: Alizarin red stain which stains calcium deposits in differentiating osteocytes,
giving a qualitative measure of osteogenic activity. A. Purchased Media: 7 days of
osteogenesis. B. Purchased Media: 14 days of osteogenesis. C. Lab-Made Media: 7 days
of osteogenesis. D. Lab-Made Media: 14 days of osteogenesis.

Figure 3-6: Fixing cells with 70% ethanol and rinsing with saline yielded better staining
even though it did not get the characteristic color of alizarin staining. A. Alizarin stain
performed using formalin for fixing and PBS for rinsing. B. Alizarin stain performed
using 70% ethanol for fixing and saline solution for rinsing.
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3.1.3

Notch Gene Expression Profile Changes During Osteogenesis
Once we determined optimal conditions for osteogenesis and had some tools to

assess differentiation, we wanted to understand how the Notch pathway regulates
osteogenesis. The first step was to profile Notch receptor expression during
differentiation. By observing the expression changes that the Notch pathway experiences
throughout osteogenesis, we can gain greater insight into the role that individual
receptors have in this process. After cells were exposed to osteogenic media for a total of
14 days, qRT-PCR results show that notch1 gene transcription remained unchanged at the
Day 7 timepoint while it decreased at Day 14. Conversely, notch3 appears to show
elevated expression levels at both Day 7 and 14 with a peak at the Day 7 timepoint
[Figure 3-7].
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Figure 3-7: Characterization of notch1 and notch3 expression in samples cultured in the
Lab-Made Media. A qRT-PCR observing the difference in notch1 expression between
Day 0 and Day 7 samples (p=0.441873). B qRT-PCR observing the difference in notch1
expression between Day 0 and Day 14 samples (p=0.019794). C qRT-PCR observing the
difference in notch3 expression between Day 0 and Day 7 samples (p=0.001278). D qRTPCR observing the difference in notch3 expression between Day 0 and Day 14 samples
(p=0.007865). Experiments were run in biological triplicate with n=3.

Western blots were used to ensure that changes in notch transcript were echoed in
Notch protein expression [Figure 3-8]. We examined both full length and cleaved
version of Notch3 in order to study the activation of the receptor. There is the possibility
that Notch3 shows elevated expression but if that receptor is not being activated then it
will not have an effect on osteogenesis. This data shows that activated (cleaved) Notch3
visually suggests an increase in protein expression through 14 days of osteogenesis. The
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consistent rise in GAPDH expression during osteogenesis brings questions to GAPDH’s
effectiveness as a loading control. While it does not maintain a consistent level of
expression, housekeeping genes such as GAPDH tend to go through variations in
expression as differentiation progresses. Given this, ImageJ analysis was performed to
normalize the Notch3 data to the GAPDH data. The analysis of this preliminary western
blot indicates that there is little change in cleaved Notch3 7 days into differentiation
while the cleaved levels of Notch3 14 days into differentiation are elevated. This suggests
that there is increased activation of the Notch3 receptor as osteogenesis progresses. As
this was the first western blot performed for this series of experiments, it will be repeated
to confirm reproducibility of results.

Figure 3-8: Western blots depicting the expression level change of the full length Notch3
receptor, the cleaved Notch3 receptor, and GAPDH at 0,7, and 14 days of osteogenesis.
n=3
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Figure 3-9: ImageJ analysis displaying the increase in cleaved Notch3 expression and a
decrease in full-length Notch3 expression after normalization to GAPDH. Data displayed
is the average value for each timepoint.
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3.1.4

Notch3 siRNA Knockdowns Suggests That Notch3 Promotes Osteogenesis
Based on the expression data for Notch1 and Notch3 during the 14 days of

osteogenesis, it was determined that the Notch1 receptor most likely plays a role in stem
cell proliferation and maintaining stemness while the Notch3 receptor seems to play a
role in promoting osteogenesis. To confirm these roles, siRNA knockdowns of each
receptor were performed and their effects on osteogenesis were observed. The siRNA
knockdown of notch3 yielded a significant decrease in alp expression when compared to
negative control samples for both day 7 and 14 of osteogenesis. However, the knockdown
seems to have only affected runx2 expression around the day 7 timepoint with day 14
samples showing transcript levels similar levels to those observed in the negative control
[Figure 3-10]. The lack of impact of the notch3 knockdown on runx2 could allude to
Notch3 only impacting Runx2 expression in the earliest stages of osteogenesis. The
notch1 knockdown was performed, but after using qRT-PCR to confirm the effects of the
knockdown, it appeared that the initial knockdown was unsuccessful and so will be
repeated for future studies [Figure 3-11].
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Figure 3-10: qRT-PCR data showing the change in gene expression of notch3, alp, and
runx2 after a notch3 siRNA knockdown when compared to a negative control. A. notch3
at day 7 of osteogenesis: p=0.0001. B. notch3 at day 14 of osteogenesis: p=0.014621. C.
alp at day 7 of osteogenesis: p=0.000113. D. alp at day 14 of osteogenesis: p=0.006541.
E. runx2 at day 7 of osteogenesis: p=0.058104. F. runx2 at day 14 of osteogenesis:
p=0.881895. Experiments were run in biological triplicate with n=3.
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Figure 3-11: qRT-PCR data showing the change in notch1 gene expression after a
notch1 knockdown when compared to a negative control. A. notch1 expression at day 7
of osteogenesis: p=0.13783. B. notch1 expression at day 14 of osteogenesis: p=0.881895.
Experiments were run in biological triplicate with n=3.
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CHAPTER 4
CONCLUSION AND FUTURE DIRECTIONS

4.1
4.1.1

Notch3 Play a Role in Regulating Adult Stem Cell Osteogenesis
Notch3 Initiated Differentiation While Notch1 Maintains Stemness

This research sought to investigate the role of the Notch1 and the Notch3 receptor
in adult stem cell osteogenesis. Through these experiments, the trends observed suggest
that Notch3 plays a role in initiating and potentially maintaining early osteogenesis due to
its increase in expression during differentiation and a decrease in differentiation
following the knockdown of Notch3. Conversely, Notch1 shows a decrease in expression
as osteogenesis progresses, suggesting that Notch1 may have a less significant role in
initiating osteogenic differentiation.

Figure 4-1: Notch1 and Notch3 both play a role in molecularly regulating early
osteogenesis in adult stem cells.
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Though the data gathered from both protein and genetic data echoed the same
trend, there were some discrepancies around whether Notch3 expression continued
increasing after day 7. Even though Notch3 expression remained elevated at day 14 of
osteogenesis when compared to day 0 samples, genetic data showed these expression
levels drop lower than day 7 while protein data showed expression higher at day 14 than
day 7. This discrepancy highlights the importance of observing expression of both
transcript and protein when studying drives of cell fate.

Figure 4-2: Osteogenesis is a process that affects transcription and translation and so
requires analysis at each level.
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This research takes a more systematic and detailed approach to studying Notch in
osteogenesis., when compared to the literature which often relies on global pathway
inhibitors to investigate the role of Notch signaling. By investigating the specific roles
that individual Notch receptors have in the process of osteogenesis, this research provides
a knowledge base that can be used to identify targets for therapeutic techniques seeking
to utilize manipulated stem cells to curb bone degeneration. With the knowledge that
Notch3 appears to initiate osteogenesis, researchers could develop cell lines that have a
natural upregulation in Notch3 expression or even develop biomaterials that can activate
Notch3 to prime hASCs for transplantation into patients suffering from bone degradation.
Even if this method of Notch3 upregulation could not be developed or if it is not
effective, the knowledge that Notch3 plays such a role in osteogenesis gives researchers
identifying the roots of bone degradation a target to investigate in bone degradation
models.
In the future, the focus of this project will be to gather more data on the effects of
Notch1 on osteogenesis by repeating siRNA knockdowns to gather definitive data on this
receptor’s role. Also, the data taken from this project will be compared to ongoing studies
seeking to investigate any potential changes to the Notch pathway in osteogenic hASCs
experiencing simulated microgravity. Bone degradation is a significant side effect
experienced by astronauts spending prolonged amounts of time in microgravity. With
NASA and other organizations preparing for longer manned missions to mars and other
celestial bodies, this phenomenon is becoming a growing concern and must be addressed.
By establishing Notch’s role in osteogenesis, it provides a research target that can be
explored in this microgravity environment to see if the pathway is affected by these
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conditions. This could provide deeper insight into the mechanism of microgravity-related
bone degradation which would lead to a potential solution to this growing issue.
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